Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Carbachol→

Carbachol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
51-83-2
Molecular formula
C6H15ClN2O2
Molecular weight
182.65 g/mol
Drug class
Direct-acting cholinergic agonistparasympathomimetic muscarinic and nicotinic receptor agonist
Mechanism of action
Directly stimulates cholinergic receptors in ocular tissues, causing pupillary constriction (miosis) and contraction of the ciliary muscle. Intraocular pressure reduction is associated with increased aqueous-humour outflow; product-specific combinations may use a pinhole effect to improve near visual acuity.
Indications / reported uses
  • Induction of miosis during ophthalmic surgery and reduction of intraocular pressure in selected ophthalmic indications, depending on the formulation
  • In combination with brimonidine in the authorised ophthalmic product for presbyopia in adults; do not attribute the fixed-combination indication to carbachol monotherapy

Sources: US DailyMed — Miostat (carbachol intraocular solution) · US DailyMed — Carbachol/brimonidine ophthalmic product · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Carbachol Environmental Risk Assessment (ERA) (the Carbachol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.